A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

Clinical trial NCT03656536 · TERMINATED

Trial details

NCT number: NCT03656536
Sponsor: Incyte Corporation
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Unresectable Cholangiocarcinoma Metastatic Cholangiocarcinoma

Start date: 2019-06-03
Primary completion: 2025-07-07
Enrollment: 167

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.